Biocryst Pharmaceuticals Inc

BCRXNASDAQ · USD
7.69USD+0.06 (+0.79%)
769

Biocryst Pharmaceuticals Inc (BCRX) Option Chain

Biocryst Pharmaceuticals Inc trades at $7.69, up 0.79%, with an IV Rank of 9.92%. This is low versus the past year, and the company carries a market cap of $1,950M in the Drug Manufacturers - Specialty & Generic industry. On the Nov 20, 2026 chain, the at the money $8.00 strike shows calls at $0.10 / $0.25 and puts at $0.50 / $0.75, both carrying about $0.25 of extrinsic value and a roughly 50% probability of expiring out of the money. Volume is heaviest on the $8.00 calls, at 70 contracts, and the $8.00 puts, at 180, as of Nov 5, 2026.

Read more

Tracking the BCRX option chain helps you see every strike and expiry on Biocryst Pharmaceuticals Inc in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of BCRX options activity at a glance. Use our scanner to monitor the BCRX option chain in real time and filter for the trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For BCRX stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where BCRX options are being actively traded, and where they are not.

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika.

2026-11-20
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
1.551000.361.691.402.706.00-21.36—0.750.000.751307098.45
22.73000.910.690.552.657.00-8.260.050.200.000.13546177.27
68.181,715700.180.000.100.258.00+4.850.500.750.310.3218039131.82
93.941,550230.130.000.050.209.00+17.96—3.101.311.790796.06
99.403,38200.250.00—0.2510.00+31.061.204.002.310.29000.60

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →

Stock Statistics

  • IndustryDrug Manufacturers - Specialty & Generic
  • SectorHealthcare
  • IV Rank9.92% Low
  • Market cap (M$)1,950
  • 52 weeks high-32.00%
  • 52 weeks low22.47%
  • Analyst recommendationStrong Buy
    1.36
  • Target price$20.45
    167.23% above the current stock price
  • Dividend—
  • Payout ratio0.00%
  • Earnings date2026-11-04
  • P/E—
  • Future P/E13.56
  • EPS (ttm)-1.42
  • EPS growth next 5 years-21.46%

As of Nov 5, 2026